Table 7.
Examples of EV use in preclinical studies related to the treatment of skin dysfunctions.
| Source of EVs | Model | Major outcomes | References |
|---|---|---|---|
| Human iPSCs | In vitro model of skin aging | Increased proliferation and migration of skin fibroblasts Decline in UVB-stimulated photoaging Decreased level of matrix-degrading enzymes |
(224) |
| Human iPSCs-derived MSCs | In vivo rat skin wound healing model | Enhanced angiogenesis Increased proliferation of the skin Improved reepithelialisation |
(225) |
| Human UC-MSCs | In vivo murine full-thickness skin wound model | Promoted proliferation and migrative of endothelial cells and skin fibroblast Improved re-epithelialisation Reduced level of proliferation suppressor genes |
(226) |
| In vivo murine model of psoriasis | Reduction of excessive epidermis proliferation Decreased level of pro-inflammatory cytokines |
(227) | |
| Human BM-MSCs | In vitro | Promoted viability of fibroblast, keratinocyte, and endothelial cells Induced endothelial cell migration |
(228) |
| In vivo murine model of diabetic skin healing | Accelerated wound closure Increased epithelial thickness |
||
| In vivo rat diabetic wound healing model | Increased macrophage M2 polarization Enhanced angiogenesis and healing Suppressed level of pro-inflammatory factors |
(229) | |
| Human AT-MSCs | In vivo murine model of atopic dermatitis | Decreased number of eosinophils and serum IgE Decreased level of pro-inflammatory cytokines Reduced inflammation |
(230) |
AT-MSCs, adipose derived MSCs; BM-MSCs, bone marrow MSCs; iPSCs, induced pluripotent stem cells; MSCs, mesenchymal stem/stromal cells; UC-MSCs, umbilical cord Wharton’s jelly MSCs.